Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Synthesis and characterization of the colistin peptide polymyxin E1 and related antimicrobial peptides.
Kline T, Holub D, Therrien J, Leung T, Ryckman D. Kline T, et al. Among authors: ryckman d. J Pept Res. 2001 Mar;57(3):175-87. doi: 10.1111/j.1399-3011.2001.00835.x. J Pept Res. 2001. PMID: 11298918
A prodrug approach toward the development of water soluble fluoroquinolones and structure--activity relationships of quinoline-3-carboxylic acids.
Baker WR, Cai S, Dimitroff M, Fang L, Huh KK, Ryckman DR, Shang X, Shawar RM, Therrien JH. Baker WR, et al. J Med Chem. 2004 Sep 9;47(19):4693-709. doi: 10.1021/jm0497895. J Med Chem. 2004. PMID: 15341485
Pharmacokinetic and Pharmacodynamic Comparison of Intravenous and Inhaled Caspofungin.
Yu IG, O'Brien SE, Ryckman DM. Yu IG, et al. Among authors: ryckman dm. J Aerosol Med Pulm Drug Deliv. 2020 Sep 24. doi: 10.1089/jamp.2020.1645. Online ahead of print. J Aerosol Med Pulm Drug Deliv. 2020. PMID: 32985935
Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.
Drygin D, Haddach M, Pierre F, Ryckman DM. Drygin D, et al. Among authors: ryckman dm. J Med Chem. 2012 Oct 11;55(19):8199-208. doi: 10.1021/jm3009234. Epub 2012 Sep 4. J Med Chem. 2012. PMID: 22924342 No abstract available.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, Huser N, Proffitt C, Bliesath J, Haddach M, Schwaebe MK, Ryckman DM, Rice WG, Schmitt C, Lowe SW, Johnstone RW, Pearson RB, McArthur GA, Hannan RD. Bywater MJ, et al. Among authors: ryckman dm. Cancer Cell. 2012 Jul 10;22(1):51-65. doi: 10.1016/j.ccr.2012.05.019. Cancer Cell. 2012. PMID: 22789538 Free PMC article.
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.
Haddach M, Schwaebe MK, Michaux J, Nagasawa J, O'Brien SE, Whitten JP, Pierre F, Kerdoncuff P, Darjania L, Stansfield R, Drygin D, Anderes K, Proffitt C, Bliesath J, Siddiqui-Jain A, Omori M, Huser N, Rice WG, Ryckman DM. Haddach M, et al. Among authors: ryckman dm. ACS Med Chem Lett. 2012 May 8;3(7):602-6. doi: 10.1021/ml300110s. eCollection 2012 Jul 12. ACS Med Chem Lett. 2012. PMID: 24900516 Free PMC article.
Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.
Pierre F, Regan CF, Chevrel MC, Siddiqui-Jain A, Macalino D, Streiner N, Drygin D, Haddach M, O'Brien SE, Rice WG, Ryckman DM. Pierre F, et al. Among authors: ryckman dm. Bioorg Med Chem Lett. 2012 May 1;22(9):3327-31. doi: 10.1016/j.bmcl.2012.02.099. Epub 2012 Mar 6. Bioorg Med Chem Lett. 2012. PMID: 22460033
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Bliesath J, Huser N, Omori M, Bunag D, Proffitt C, Streiner N, Ho C, Siddiqui-Jain A, O'Brien SE, Lim JK, Ryckman DM, Anderes K, Rice WG, Drygin D. Bliesath J, et al. Among authors: ryckman dm. Cancer Lett. 2012 Sep 1;322(1):113-8. doi: 10.1016/j.canlet.2012.02.032. Epub 2012 Mar 2. Cancer Lett. 2012. PMID: 22387988
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.
Haddach M, Michaux J, Schwaebe MK, Pierre F, O'Brien SE, Borsan C, Tran J, Raffaele N, Ravula S, Drygin D, Siddiqui-Jain A, Darjania L, Stansfield R, Proffitt C, Macalino D, Streiner N, Bliesath J, Omori M, Whitten JP, Anderes K, Rice WG, Ryckman DM. Haddach M, et al. Among authors: ryckman dm. ACS Med Chem Lett. 2011 Dec 27;3(2):135-9. doi: 10.1021/ml200259q. eCollection 2012 Feb 9. ACS Med Chem Lett. 2011. PMID: 24900437 Free PMC article.
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, Ho CB, Anderes K, Proffitt C, O'Brien SE, Lim JK, Von Hoff DD, Ryckman DM, Rice WG, Drygin D. Siddiqui-Jain A, et al. Among authors: ryckman dm. Mol Cancer Ther. 2012 Apr;11(4):994-1005. doi: 10.1158/1535-7163.MCT-11-0613. Epub 2012 Jan 20. Mol Cancer Ther. 2012. PMID: 22267551 Free article.
39 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback